There are currently 45 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
NCT05001737
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Gender:
All
Ages:
Between 6 months and 80 years
Trial Updated:
04/16/2024
Locations: UAB Hospital, Birmingham, Alabama +48 locations
Conditions: Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Register for Updates
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
NCT01931644
Recruiting
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/15/2024
Locations: Sanguine Biosciences, Los Angeles, California
Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Register for Updates
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691
Recruiting
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2024
Locations: Research Site, Anniston, Alabama +189 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
NCT05856448
Recruiting
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/11/2024
Locations: University of Arizona College of Medicine - Tucson, Tucson, Arizona +56 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
NCT06041568
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies. Participants will be given imvotamab through a vein (i.e., intravenously).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: TriWest Research Associates, San Diego, California +9 locations
Conditions: Systemic Lupus Erythematosus, Lupus Erythematosus
Register for Updates
A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)
NCT06153095
Recruiting
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with active, refractory lupus nephritis and systemic lupus erythematosus. IMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Individual... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: University of California, Los Angeles (UCLA) Medical Center, Los Angeles, California +4 locations
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Register for Updates
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT00198068
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
04/05/2024
Locations: Northwestern University, Chicago, Illinois +9 locations
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Register for Updates
Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
NCT06031415
Recruiting
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The primary objectives of this study are to assess the safety and tolerability of multiple ascending subcutaneous (SC) doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple SC doses of GS-0272, in participants with RA or SLE.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: Clinical Research of West Florida, Inc., Clearwater, Florida +4 locations
Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus
Register for Updates
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
NCT05638802
Recruiting
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Pinnacle Research Group LLC, Anniston, Alabama +11 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
All
Ages:
12 years and above
Trial Updated:
04/02/2024
Locations: Providence Medical Center, Burbank, California +121 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
NCT06294236
Recruiting
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2024
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Register for Updates
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus
NCT05039840
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: Study duration: 36 weeks Treatment duration: 24 weeks Visit frequency: every 2 weeks
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/28/2024
Locations: Achieve Clinical Research Site Number : 8400003, Birmingham, Alabama +55 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates